l e t t e r s nature medicine VOLUME 16 | NUMBER 3 | MARCH 2010 3 1 3 Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (encoded by Cftr) that impair its role as an apical chloride channel that supports bicarbonate transport 1 . Individuals with cystic fibrosis show retained, thickened mucus that plugs airways and obstructs luminal organs 2 as well as numerous other abnormalities that include inflammation of affected organs 1 , alterations in lipid metabolism 3 and insulin resistance 4 . Here we show that colonic epithelial cells and whole lung tissue from Cftr-deficient mice show a defect in peroxisome proliferatoractivated receptor- (PPAR-, encoded by Pparg) function that contributes to a pathological program of gene expression. Lipidomic analysis of colonic epithelial cells suggests that this defect results in part from reduced amounts of the endogenous PPAR- ligand 15-keto-prostaglandin E 2 (15-keto-PGE 2 ). Treatment of Cftr-deficient mice with the synthetic PPAR- ligand rosiglitazone partially normalizes the altered gene expression pattern associated with Cftr deficiency and reduces disease severity. Rosiglitazone has no effect on chloride secretion in the colon, but it increases expression of the genes encoding carbonic anhydrases 4 and 2 (Car4 and Car2), increases bicarbonate secretion and reduces mucus retention. These studies reveal a reversible defect in PPAR- signaling in Cftr-deficient cells that can be pharmacologically corrected to ameliorate the severity of the cystic fibrosis phenotype in mice.
Cftr knockout (Cftr tm1Unc , hereafter Cftr −/− ) mice accumulate mucus in the small bowel and colon and die from intestinal or colonic obstruction within the first 6 weeks of life 5 . Survival of the Cftr −/− mouse is partially improved by providing a low-residue elemental liquid diet (Peptamen) 6 or electrolyte lavage solution (GoLYTELY) 7 . We performed transcriptome analysis of colonic epithelial cells isolated from wild-type and Cftr −/− mice, maintaining both genotypes on GoLYTELY to exclude secondary consequences of obstruction in the Cftr −/− mice. Gene ontology analysis of downregulated genes in Cftr −/− cells revealed significant (P = 5.0 × 10 −8 ) enrichment for genes involved in lipid metabolism (Supplementary Fig. 1a ) 8 , and Kyoto Encyclopedia of Genes and Genomes pathway analysis suggested a defect in PPAR-dependent gene expression (P < 0.05). A corresponding set of genes was upregulated in Cftr −/− cells, and similar analyses revealed enrichment for functional annotations linked to inflammatory responses, despite an absence of inflammatory cells in Cftr −/− colons by standard H&E staining (data not shown). Analysis of PPAR isoforms in the intestinal tract revealed high amounts of PPAR-γ in the colon of wild-type mice (Fig. 1a) . Although a previous study reported a decrease in PPAR-γ expression in the intact colons of Cftr −/− mice 9 , we found that PPAR-γ messenger RNAs (Fig. 1a) were similar in wild-type and Cftr −/− colonic epithelial cells derived from mice maintained on GoLYTELY. We therefore tested the possibility that administration of a synthetic PPAR-γ agonist might partially restore the abnormal pattern of gene expression observed in Cftr −/− cells. Consistent with this hypothesis, transcriptome analysis of wildtype and Cftr −/− colonic epithelial cells treated with the synthetic PPAR-γ agonist rosiglitazone revealed that rosiglitazone treatment increased the expression of 107 of the 388 transcripts that were downregulated in Cftr −/− compared to wild-type cells while lowering the expression of 75 of the 328 upregulated genes ( Supplementary Fig. 1b and Supplementary Tables 1 and 2) .
We investigated whether the effect of rosiglitazone treatment could have a functional consequence by randomizing 4-week-old Cftr −/− mice to groups receiving either GoLYTELY and standard chow, water and standard chow or water and standard chow mixed with rosiglitazone (20 mg per kg body weight per day). Cftr −/− mice receiving rosiglitazone were significantly less likely to suffer from bowel obstruction than mice receiving control chow without rosiglitazone, resulting in a higher survival rate (log-rank test, P < 0.001, Fig. 1b ). Several possibilities may account for treatment failure in the 50% of mice that went on to develop obstruction, including subclinical obstruction in this subset of mice before study onset that would result in reduced feeding behavior and drug consumption. Consistent with this, the mortality rates were similar for mice treated with GoLYTELY and those treated with rosiglitazone ( Fig. 1b) .
Quantitative PCR (qPCR) confirmed both the downregulation of known PPAR target genes, including Acaa1b (encoding acetyl-CoA acyltransferase-1B), Angptl4 (encoding angiopoietin-like-4), Mgll Pharmacological correction of a defect in PPAR-γ signaling ameliorates disease severity in Cftr-deficient mice (encoding monoglyceride lipase) and Hmgcs2 (encoding 3-hydroxy-3-methylglutaryl-CoA synthase-2) 10-12 , in Cftr −/− cells and the restoration of their expression by rosiglitazone treatment ( Fig. 2a and Supplementary Fig. 2a ). Conversely, genes upregulated in Cftr −/− cells, including Cxcl1 (encoding chemokine (C-X-C motif) ligand-1), Cxcl2 (encoding chemokine (C-X-C motif) ligand-2), Reg3b (encoding regenerating islet-derived-3β) and Reg3g (encoding regenerating islet-derived-3γ), were suppressed by rosiglitazone ( Supplementary  Fig. 3a ). We generated mice lacking PPAR-γ in the intestinal epithelium to establish the receptor specificity of the effects of rosiglitazone in the gastrointestinal tract. We mated mice carrying the exon 2 loxP site-flanked (floxed) allele of Pparg with mice in which the promoter of the gene encoding villin-1 (Vil1) drives intestinal-epithelial cell (IEC)-specific expression of Cre recombinase 13 , resulting in more than 95% recombination of the floxed Pparg locus in colonic epithelial cells with a corresponding loss of PPAR-γ protein ( Supplementary  Fig. 2b ). We refer to Vil1-Cre -Pparg f/f mice as Pparg f/f and Vil1-Cre + Pparg f/f mice as Pparg IEC−/− . Similar mice were previously described and were noted to have accumulation of Alcian blue-staining mucins in the colon and increased sensitivity to chemical colitis 14 .
Assessment of gene expression in Pparg IEC−/− mice showed lower expression of the PPAR-γ target genes identified in the Cftr −/− mice and no induction by rosiglitazone ( Fig. 2b) . Conversely, genes upregulated in the Cftr −/− mice were upregulated in Pparg IEC−/− cells and were not suppressed by rosiglitazone ( Supplementary Fig. 3b ). These results confirmed that rosiglitazone acts through colonic epithelial cell PPAR-γ to affect target gene expression and suggested that loss of PPAR-γ activity in colonic epithelial cells contributes to cellautonomous activation of inflammatory response genes. We crossed Cftr −/− mice with Pparg IEC−/− mice to investigate a functional interaction between PPAR-γ and the cystic fibrosis phenotype. Mice with the combined deletion (Cftr −/− ;Pparg IEC−/− ) were smaller at 30 d of age compared to littermate controls (Cftr −/− ;Pparg f/f ) in both male and female groups (P < 0.001), whereas there was no weight difference between Pparg f/f control and Pparg IEC−/− mice ( Supplementary  Fig. 4a ). Cftr −/− ;Pparg IEC−/− mice showed a similarly poor survival to Cftr −/− mice when switched from GoLYTELY to water at 4 weeks of age, as expected (data not shown). However, when we switched Cftr −/− ;Pparg f/f mice and Cftr −/− ;Pparg IEC−/− mice from GoLYTELY to water at 8 weeks of age, Cftr −/− ;Pparg IEC−/− mice were more prone to death than control Cftr −/− ;Pparg f/f mice (logrank test, P < 0.01)( Fig. 2c) and showed massive mucus accumulation resulting in bowel obstruction ( Fig. 2d and Supplementary  Fig. 4b ). Rosiglitazone treatment had no effect on survival of Cftr −/− ;Pparg IEC−/− mice but did prolong survival of 8-weekold Cftr −/− ;Pparg f/f mice (log-rank test, P < 0.05). Furthermore, the ability of rosiglitazone to suppress mucus accumulation in Cftr −/− ;Pparg f/f mice was absent in Cftr −/− ; Pparg IEC−/− mice ( Fig. 2d) , indicating that rosiglitazone acts through PPAR-γ expressed in epithelial cells to ameliorate the obstructive phenotype.
Expression levels of PPAR-γ target genes were also low in tissue from the lungs of Cftr −/− mice, exemplified by Angptl4 and Acaa1b, and were restored by rosiglitazone treatment ( Fig. 2e) . To address whether there is a defect in PPAR-γ function in human cells bearing mutations that are common causes of cystic fibrosis, we made use of the IB3-1, C38 and S9 cell lines. IB3-1 cells are human bronchial epithelial cells derived from a compound heterozygote individual with cystic fibrosis (∆F508/W1282X) expressing only ∆F508 CFTR protein, owing to the instability of the W1282X mutation 15 . The C38 cell line was derived from IB3-1 cells by transduction with a functional N-terminal truncated CFTR allele that restores chloride secretion, whereas the S9 cell line was transduced with a full-length version of CFTR. Although these cells are aneuploid and show a number of differences with respect to primary bronchial epithelial cells, they allow a direct determination of CFTR-dependent alterations by comparison to the parental line 16 . Notably, basal levels of PPAR-γ target genes, such as ANGPTL4 and ADFP, were low in the IB3-1 cell line compared to the rescued C38 cell line and were restored toward baseline by rosiglitazone treatment (Fig. 2f) . We obtained similar results in S9 cells ( Supplementary Fig. 5 ).
We performed ion transport studies to determine whether rosiglitazone treatment ameliorates the colonic phenotype of Cftr −/− mice by affecting chloride secretion. Colonic tissue from Cftr −/− mice or human colonic T84 cells treated with a CFTR inhibitor (CFTR inh -172) showed the expected defect in forskolin-and calcium-dependent stimulated chloride secretion, but this defect was not affected by rosiglitazone treatment (Supplementary Fig. 6 and data not shown). We therefore systematically searched for rosiglitazone-inducible, PPAR-γ-dependent genes that might be involved in other types of compensatory ion transport ( Fig. 3a and Supplementary Fig. 7) . These studies identified Car4 and Car2 as of potential interest, because they were rosiglitazone-inducible in wild-type but not Pparg IEC−/− cells and have established roles in bicarbonate production and secretion in the intestine 17, 18 . We confirmed low protein amounts of Car4 and Car2 in the Pparg IEC−/− cells compared to wild-type cells under basal conditions, and this basal expression was increased by rosiglitazone treatment in wild-type cells (Fig. 3b) . Furthermore, Car4 and Car2 transcript and protein levels were reduced in colonic epithelial cells derived from Cftr −/− mice in comparison to cells derived from wild-type mice and were induced by treatment with rosiglitazone ( Fig. 3c,d) . Car4 and Car2 mRNA levels were also low in lungs of Cftr −/− mice and were induced by rosiglitazone ( Fig. 3e) . Likewise, rosiglitazone treatment was capable of inducing the homologous genes (CA4 and CA2) in the human lung epithelial cell line Calu3 (Fig. 3f ). Next, we investigated whether increased carbonic anhydrase gene expression correlated with physiologic consequences by measuring bicarbonate secretion induced by the heat-stable enterotoxin of Escherichia coli 19 in colonic tissue from Cftr −/− mice. These studies showed significantly more bicarbonate secretion in colonic tissue derived from rosiglitazone-treated Cftr −/− mice compared to untreated control mice (Fig. 3g) .
The observation that Cftr −/− colonic epithelial cells show a defect in PPAR-γ-dependent gene expression but normal amounts of PPAR-γ protein suggested a defect in PPAR-γ function. We performed chromatin immunoprecipitation (ChIP) experiments to quantify PPAR-γ occupancy of PPAR response elements in wild-type and Cftr −/− colonic epithelial cells. We evaluated known PPAR-γ binding sites in the case of the Hmgcs2 and Angptl4 genes 20, 21 . We identified putative PPAR response elements (PPREs) in the Acaa1b, Mgll and Car4 genes by sequence analysis and confirmed that they confer PPAR-γ-dependent transcriptional responses in enhancer assays (Supplementary Fig. 8) . These experiments showed equivalent binding of PPAR-γ to promoter-proximal and intronic elements in the Angptl4, Hmgcs2 and Car4 genes and reduced binding of PPAR-γ to distal elements in the Acaa1b and Mgll genes in Cftr −/− cells as compared to wild-type cells ( Fig. 4a) . This binding was clearly specific for PPAR-γ, because we did not observe it in Pparg IEC−/− cells (Fig. 4b) . Thus, the expression of PPAR-γ target genes was low in Cftr −/− cells even in cases in which genomic PPAR-γ binding to response elements was equivalent to that in wild-type cells. We performed ChIP for thyroid hormone receptorassociated protein-220 (TRAP220), a nuclear receptor coactivator that is a component of the mediator complex, to confirm a functional defect in DNA-bound PPAR-γ. Because TRAP220 interacts directly with PPAR-γ in a ligand-dependent manner through LXXLL nuclear receptor-interacting domains 22, 23 , its PPAR-dependent interaction with PPREs in vivo provided an assessment of the functional activity state of PPAR-γ. The binding of TRAP220 was reduced at all PPREs examined in Cftr −/− colonic epithelial cells compared to wild-type cells, including at sites at which PPAR-γ binding itself was equivalent (Fig. 4c) . In contrast, binding of TRAP220 to the promoter of the gene encoding β-actin (Actb) was similar in both cell types (Fig. 4c) . Evidence that recruitment of TRAP220 to PPREs in wild-type cells was dependent on PPAR-γ included the marked reduction of TRAP220 binding to these sites in PPAR-γ IEC−/− cells, with no alteration at the Actb promoter (Fig. 4d) .
The reduced recruitment of TRAP220 in Cftr −/− colonic epithelial cells raised the possibility that the abundance endogenous fatty acid metabolites that serve as activating ligands for PPAR-γ might be reduced in the context of Cftr deficiency. Therefore, we used both gas chromatography and liquid chromatography mass spectrometry to quantify fatty acids and eicosanoids in wild-type and Cftr −/− colonic epithelial cells in vivo. Among the 94 eicosanoid analytes that we quantified, 15-hydroxyeicosatetraenoic acid (15-HETE) and 15-keto-PGE 2 were the two most abundant species present in wild-type cells that are capable of activating PPAR-γ in the low micromolar range 24, 25 . Although 15-HETE abundance was unchanged, 15-keto-PGE 2 abundance was reduced by about 65% in Cftr −/− cells (P < 0.002, Fig. 4e ). In concert with this finding, expression of 15-hydroxyprostaglandin dehydrogenase (Hpgd), which is required for synthesis of 15-keto-PGE 2 from PGE 2 , was also reduced by 70% in Cftr −/− cells (Fig. 4f) . Using induction of Angptl4 expression as a functional assay, we found that15-keto-PGE 2 promoted more sustained induced expression than did 15-HETE (Fig. 4g) .
Together, these studies build upon previous work suggesting reduced expression and function of PPAR-γ in colon 12 and airway epithelial cells 26 in the setting of CFTR deficiency. Here we provide evidence for a reversible defect in PPAR-γ function in Cftr −/− colon and lung that contributes to a pathogenic program of gene expression. Lipidomic analysis suggests that this defect results, at least in part, from a reduction in the abundance of endogenous PPAR-γ ligands, which include 15-keto-PGE 2 . The corresponding decrease in Hpgd expression raises the possibility that reduced conversion of PGE 2 to 15-keto-PGE 2 might contribute to the increased quantities of PGE 2 observed in individuals with cystic fibrosis 27 .
The functional defect in PPAR-γ activity seems to contribute to the intestinal phenotype of Cftr −/− mice on the basis of the ability of rosiglitazone to lower the mortality and the increased disease severity in Cftr −/− ;Pparg IEC−/− mice. Owing to the large number of down-and upregulated genes that are 'corrected' in Cftr −/− colonic epithelial cells by rosiglitazone treatment, it is likely that multiple genes contribute to phenotype attenuation. The mechanisms connecting Cftr deficiency to reduced Hpgd expression, and the identities of PPAR-γ regulatory elements in many of the key target genes, remain to be established.
Mucus accumulation and overexpression of inflammatory response genes are two relevant pathogenic features of cystic fibrosis that are inhibited by rosiglitazone in a PPAR-γ-dependent manner. Previous studies have shown that PPAR-γ agonists suppress proinflammatory mediators and neutrophil recruitment in bronchoalveolar lavage fluid after Psuedomonas aeruginosa infection 26 . Although inhibition of inflammation is a well-established function of PPAR-γ in several cell types and tissues, including colon 28, 29 , its roles in the regulation of mucus have not been previously described. Several mechanisms have been proposed to account for mucus accumulation in cystic fibrosis, including isotonic contraction of the air-surface layer 30 and reduced mucus clearance possibly due to defects in bicarbonate transport 31 . The effects of rosiglitazone on bicarbonate secretion and mucus accumulation in the colon are consistent with the hypothesis that luminal bicarbonate has a key role in the normal transition of mucins from the compacted to expanded state 32 . PPAR-γ ligands have been considered for treatment of cystic fibrosis on the basis of their anti-inflammatory activities 33 , but clinical efficacy remains to be established. The present studies suggest that additional parameters should be considered in the design of clinical trials. The relatively high rate of treatment failure in Cftr −/− mice suggests that appropriate dosing may be crucial, as documented in clinical studies of the effect of ibuprofen on neutrophil migration into the lungs of individuals with cystic fibrosis 34 . Differences in the effects of 15-keto-PGE 2 and 15-HETE on ANGPTL4 expression raise the possibility that not all PPAR-γ ligands are equivalent with respect to restoration of functional defects in the setting of CFTR deficiency. Finally, measurement of levels of 15-keto-PGE 2 may provide a biomarker for selecting patients most likely to benefit from PPAR-γ agonists.
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